371 related articles for article (PubMed ID: 26624980)
1. SRC family kinase FYN promotes the neuroendocrine phenotype and visceral metastasis in advanced prostate cancer.
Gururajan M; Cavassani KA; Sievert M; Duan P; Lichterman J; Huang JM; Smith B; You S; Nandana S; Chu GC; Mink S; Josson S; Liu C; Morello M; Jones LW; Kim J; Freeman MR; Bhowmick N; Zhau HE; Chung LW; Posadas EM
Oncotarget; 2015 Dec; 6(42):44072-83. PubMed ID: 26624980
[TBL] [Abstract][Full Text] [Related]
2. Fyn is downstream of the HGF/MET signaling axis and affects cellular shape and tropism in PC3 cells.
Jensen AR; David SY; Liao C; Dai J; Keller ET; Al-Ahmadie H; Dakin-Haché K; Usatyuk P; Sievert MF; Paner GP; Yala S; Cervantes GM; Natarajan V; Salgia R; Posadas EM
Clin Cancer Res; 2011 May; 17(10):3112-22. PubMed ID: 21364031
[TBL] [Abstract][Full Text] [Related]
3. Roles of Fyn in pancreatic cancer metastasis.
Chen ZY; Cai L; Bie P; Wang SG; Jiang Y; Dong JH; Li XW
J Gastroenterol Hepatol; 2010 Feb; 25(2):293-301. PubMed ID: 19968749
[TBL] [Abstract][Full Text] [Related]
4. SOCS1 inhibits migration and invasion of prostate cancer cells, attenuates tumor growth and modulates the tumor stroma.
Villalobos-Hernandez A; Bobbala D; Kandhi R; Khan MG; Mayhue M; Dubois CM; Ferbeyre G; Saucier C; Ramanathan S; Ilangumaran S
Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):36-47. PubMed ID: 27779203
[TBL] [Abstract][Full Text] [Related]
5. BMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro.
Dai Y; Siemann DW
Mol Cancer Ther; 2010 Jun; 9(6):1554-61. PubMed ID: 20515943
[TBL] [Abstract][Full Text] [Related]
6. Yes-mediated phosphorylation of focal adhesion kinase at tyrosine 861 increases metastatic potential of prostate cancer cells.
Chatterji T; Varkaris AS; Parikh NU; Song JH; Cheng CJ; Schweppe RE; Alexander S; Davis JW; Troncoso P; Friedl P; Kuang J; Lin SH; Gallick GE
Oncotarget; 2015 Apr; 6(12):10175-94. PubMed ID: 25868388
[TBL] [Abstract][Full Text] [Related]
7. Reduced c-Met expression by an adenovirus expressing a c-Met ribozyme inhibits tumorigenic growth and lymph node metastases of PC3-LN4 prostate tumor cells in an orthotopic nude mouse model.
Kim SJ; Johnson M; Koterba K; Herynk MH; Uehara H; Gallick GE
Clin Cancer Res; 2003 Nov; 9(14):5161-70. PubMed ID: 14613995
[TBL] [Abstract][Full Text] [Related]
8. Suppression of Akt1-β-catenin pathway in advanced prostate cancer promotes TGFβ1-mediated epithelial to mesenchymal transition and metastasis.
Gao F; Alwhaibi A; Sabbineni H; Verma A; Eldahshan W; Somanath PR
Cancer Lett; 2017 Aug; 402():177-189. PubMed ID: 28602980
[TBL] [Abstract][Full Text] [Related]
9. FOXA1 inhibits prostate cancer neuroendocrine differentiation.
Kim J; Jin H; Zhao JC; Yang YA; Li Y; Yang X; Dong X; Yu J
Oncogene; 2017 Jul; 36(28):4072-4080. PubMed ID: 28319070
[TBL] [Abstract][Full Text] [Related]
10. Histone demethylase PHF8 drives neuroendocrine prostate cancer progression by epigenetically upregulating FOXA2.
Liu Q; Pang J; Wang LA; Huang Z; Xu J; Yang X; Xie Q; Huang Y; Tang T; Tong D; Liu G; Wang L; Zhang D; Ma Q; Xiao H; Lan W; Qin J; Jiang J
J Pathol; 2021 Jan; 253(1):106-118. PubMed ID: 33009820
[TBL] [Abstract][Full Text] [Related]
11. MAN2A1-FER Fusion Gene Is Expressed by Human Liver and Other Tumor Types and Has Oncogenic Activity in Mice.
Chen ZH; Yu YP; Tao J; Liu S; Tseng G; Nalesnik M; Hamilton R; Bhargava R; Nelson JB; Pennathur A; Monga SP; Luketich JD; Michalopoulos GK; Luo JH
Gastroenterology; 2017 Oct; 153(4):1120-1132.e15. PubMed ID: 28245430
[TBL] [Abstract][Full Text] [Related]
12. Amplification of MUC1 in prostate cancer metastasis and CRPC development.
Wong N; Major P; Kapoor A; Wei F; Yan J; Aziz T; Zheng M; Jayasekera D; Cutz JC; Chow MJ; Tang D
Oncotarget; 2016 Dec; 7(50):83115-83133. PubMed ID: 27825118
[TBL] [Abstract][Full Text] [Related]
13. Smad4 deletion in blood vessel endothelial cells promotes ovarian cancer metastasis.
Yang J; Wang Y; Zeng Z; Qiao L; Zhuang L; Gao Q; Ma D; Huang X
Int J Oncol; 2017 May; 50(5):1693-1700. PubMed ID: 28393199
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of manganese superoxide dismutase (SOD2) is a common pathway for neuroendocrine differentiation in prostate cancer cells.
Quirós I; Sáinz RM; Hevia D; García-Suárez O; Astudillo A; Rivas M; Mayo JC
Int J Cancer; 2009 Oct; 125(7):1497-504. PubMed ID: 19507253
[TBL] [Abstract][Full Text] [Related]
15. Differential requirement for Src family tyrosine kinases in the initiation, progression, and metastasis of prostate cancer.
Gelman IH; Peresie J; Eng KH; Foster BA
Mol Cancer Res; 2014 Oct; 12(10):1470-9. PubMed ID: 25053806
[TBL] [Abstract][Full Text] [Related]
16. Alternative RNA splicing of the MEAF6 gene facilitates neuroendocrine prostate cancer progression.
Lee AR; Li Y; Xie N; Gleave ME; Cox ME; Collins CC; Dong X
Oncotarget; 2017 Apr; 8(17):27966-27975. PubMed ID: 28427194
[TBL] [Abstract][Full Text] [Related]
17. The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer.
Singh N; Ramnarine VR; Song JH; Pandey R; Padi SKR; Nouri M; Olive V; Kobelev M; Okumura K; McCarthy D; Hanna MM; Mukherjee P; Sun B; Lee BR; Parker JB; Chakravarti D; Warfel NA; Zhou M; Bearss JJ; Gibb EA; Alshalalfa M; Karnes RJ; Small EJ; Aggarwal R; Feng F; Wang Y; Buttyan R; Zoubeidi A; Rubin M; Gleave M; Slack FJ; Davicioni E; Beltran H; Collins C; Kraft AS
Nat Commun; 2021 Dec; 12(1):7349. PubMed ID: 34934057
[TBL] [Abstract][Full Text] [Related]
18. Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1.
Hsu EC; Rice MA; Bermudez A; Marques FJG; Aslan M; Liu S; Ghoochani A; Zhang CA; Chen YS; Zlitni A; Kumar S; Nolley R; Habte F; Shen M; Koul K; Peehl DM; Zoubeidi A; Gambhir SS; Kunder CA; Pitteri SJ; Brooks JD; Stoyanova T
Proc Natl Acad Sci U S A; 2020 Jan; 117(4):2032-2042. PubMed ID: 31932422
[TBL] [Abstract][Full Text] [Related]
19. Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors.
Qi J; Nakayama K; Cardiff RD; Borowsky AD; Kaul K; Williams R; Krajewski S; Mercola D; Carpenter PM; Bowtell D; Ronai ZA
Cancer Cell; 2010 Jul; 18(1):23-38. PubMed ID: 20609350
[TBL] [Abstract][Full Text] [Related]
20. Aberrant activation of hepatocyte growth factor/MET signaling promotes β-catenin-mediated prostatic tumorigenesis.
Aldahl J; Mi J; Pineda A; Kim WK; Olson A; Hooker E; He Y; Yu EJ; Le V; Lee DH; Geradts J; Sun Z
J Biol Chem; 2020 Jan; 295(2):631-644. PubMed ID: 31819003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
